Mutant TP53 in Duodenal Samples of Pancreatic Juice from Patients with Pancreatic Cancer or High-grade Dysplasia

Overview

Journal Clin Gastroenterol Hepatol

Specialty Gastroenterology

Date 2012 Dec 4

PMID 23200980

Citations 88

Authors

Mitsuro Kanda

Yoshihiko Sadakari

Michael Borges

Mark Topazian

James Farrell

Sapna Syngal

Jeffrey Lee

Ihab Kamel

Anne Marie Lennon

Spencer Knight

Sho Fujiwara

Ralph H Hruban

Marcia Irene Canto

Michael Goggins

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Imaging tests can identify patients with pancreatic neoplastic cysts but not microscopic dysplasia. We investigated whether mutant TP53 can be detected in duodenal samples of secretin-stimulated pancreatic juice, and whether this assay can be used to screen for high-grade dysplasia and invasive pancreatic cancer.

Methods: We determined the prevalence of mutant TP53 in microdissected pancreatic intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and invasive adenocarcinomas. TP53 mutations were quantified by digital high-resolution melt-curve analysis and sequencing of secretin-stimulated pancreatic juice samples, collected from duodena of 180 subjects enrolled in Cancer of the Pancreas Screening trials; patients were enrolled because of familial and/or inherited predisposition to pancreatic cancer, or as controls.

Results: TP53 mutations were identified in 9.1% of intermediate-grade IPMNs (2 of 22), 17.8% of PanIN-2 (8 of 45), 38.1% of high-grade IPMNs (8 of 21), 47.6% of PanIN-3 (10 of 21), and 75% of invasive pancreatic adenocarcinomas (15 of 20); no TP53 mutations were found in PanIN-1 lesions or low-grade IPMNs. TP53 mutations were detected in duodenal samples of pancreatic juice from 29 of 43 patients with pancreatic ductal adenocarcinoma (67.4% sensitivity; 95% confidence interval, 0.52-0.80) and 4 of 8 patients with high-grade lesions (PanIN-3 and high-grade IPMN). No TP53 mutations were identified in samples from 58 controls or 55 screened individuals without evidence of advanced lesions.

Conclusions: We detected mutant TP53 in secretin-stimulated pancreatic juice samples collected from duodena of patients with high-grade dysplasia or invasive pancreatic cancer. Tests for mutant TP53 might be developed to improve the diagnosis of and screening for pancreatic cancer and high-grade dysplasia. Clinical Trial numbers: NCT00438906 and NCT00714701.

Citing Articles

Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges.

Pian L, Song M, Wang T, Qi L, Peng T, Xie K Front Endocrinol (Lausanne). 2025; 15():1401829.

PMID: 39839479 PMC: 11746065. DOI: 10.3389/fendo.2024.1401829.

Duodenal Fluid Analysis as a Rewarding Approach to Detect Low-Abundance Mutations in Biliopancreatic Cancers.

Tavano F, Latiano A, Palmieri O, Gioffreda D, Latiano T, Gentile A Int J Mol Sci. 2024; 25(15).

PMID: 39126005 PMC: 11312909. DOI: 10.3390/ijms25158436.

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.

Stefanoudakis D, Frountzas M, Schizas D, Michalopoulos N, Drakaki A, Toutouzas K Curr Issues Mol Biol. 2024; 46(4):2827-2844.

PMID: 38666907 PMC: 11049225. DOI: 10.3390/cimb46040177.

The role of biomarkers in the early detection of pancreatic cancer.

Goggins M Fam Cancer. 2024; 23(3):309-322.

PMID: 38662265 PMC: 11309746. DOI: 10.1007/s10689-024-00381-4.

New avenues for the treatment of immunotherapy-resistant pancreatic cancer.

de Oliveira Silva L, Bueno Lemos F, Silva Luz M, Rocha Pinheiro S, Calmon M, Lima Correa Santos G World J Gastrointest Oncol. 2024; 16(4):1134-1153.

PMID: 38660642 PMC: 11037047. DOI: 10.4251/wjgo.v16.i4.1134.

References

Raimondi S, Maisonneuve P, Lowenfels A . Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009; 6(12):699-708. DOI: 10.1038/nrgastro.2009.177. View

Brune K, Abe T, Canto M, OMalley L, Klein A, Maitra A . Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006; 30(9):1067-76. PMC: 2746409. DOI: pas.0000213265.84725.0b. View

Hruban R, Maitra A, Goggins M . Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008; 1(4):306-16. PMC: 2480542. View

Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T . Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology. 2005; 128(7):2124-30. DOI: 10.1053/j.gastro.2005.03.006. View

Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T . Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res. 1999; 5(5):1147-53. View

Leary R, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C . Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010; 2(20):20ra14. PMC: 2858564. DOI: 10.1126/scitranslmed.3000702. View

Jones S, Zhang X, Parsons D, Cheng-Ho Lin J, Leary R, Angenendt P . Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-6. PMC: 2848990. DOI: 10.1126/science.1164368. View

Brentnall T, Bronner M, Byrd D, Haggitt R, Kimmey M . Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999; 131(4):247-55. DOI: 10.7326/0003-4819-131-4-199908170-00003. View

Redston M, Caldas C, Seymour A, Hruban R, Da Costa L, Yeo C . p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994; 54(11):3025-33. View

10.

Verna E, Hwang C, Stevens P, Rotterdam H, Stavropoulos S, Sy C . Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010; 16(20):5028-37. DOI: 10.1158/1078-0432.CCR-09-3209. View

11.

Canto M, Goggins M, Yeo C, Griffin C, Axilbund J, Brune K . Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004; 2(7):606-21. DOI: 10.1016/s1542-3565(04)00244-7. View

12.

Canto M, Hruban R, Fishman E, Kamel I, Schulick R, Zhang Z . Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012; 142(4):796-804. PMC: 3321068. DOI: 10.1053/j.gastro.2012.01.005. View

13.

Klein A, Brune K, Petersen G, Goggins M, Tersmette A, Offerhaus G . Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64(7):2634-8. DOI: 10.1158/0008-5472.can-03-3823. View

14.

Canto M, Goggins M, Hruban R, Petersen G, Giardiello F, Yeo C . Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006; 4(6):766-81. DOI: 10.1016/j.cgh.2006.02.005. View

15.

Kaino M, Kondoh S, Okita S, Hatano S, Shiraishi K, Kaino S . Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors. Pancreas. 1999; 18(3):294-9. DOI: 10.1097/00006676-199904000-00011. View

16.

Kanda M, Knight S, Topazian M, Syngal S, Farrell J, Lee J . Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut. 2012; 62(7):1024-33. PMC: 3893110. DOI: 10.1136/gutjnl-2012-302823. View

17.

Poley J, Kluijt I, Gouma D, Harinck F, Wagner A, Aalfs C . The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009; 104(9):2175-81. DOI: 10.1038/ajg.2009.276. View

18.

Haeno H, Gonen M, Davis M, Herman J, Iacobuzio-Donahue C, Michor F . Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012; 148(1-2):362-75. PMC: 3289413. DOI: 10.1016/j.cell.2011.11.060. View

19.

Ludwig E, Olson S, Bayuga S, Simon J, Schattner M, Gerdes H . Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011; 106(5):946-54. PMC: 3683863. DOI: 10.1038/ajg.2011.65. View

20.

Shi C, Hruban R . Intraductal papillary mucinous neoplasm. Hum Pathol. 2011; 43(1):1-16. DOI: 10.1016/j.humpath.2011.04.003. View